


FORM PCT/1390 (REV 11-2000)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 159-72
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) <b>10/088563</b>
INTERNATIONAL APPLICATION NO. PCT/JPO00/05170	INTERNATIONAL FILING DATE 02/08/2000	PRIORITY DATE CLAIMED 02/08/2000
TITLE OF INVENTION <b>KITS FOR EXTRACTING NUCLEIC ACID AND METHOD OF EXTRACTING NUCLEIC ACID BY USING THE KITS</b>		
APPLICANT(S) FOR DO/EO/US <b>YOSHIHARA, N. et al.</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The U.S. has been elected by the expiration of 19 months from the priority date (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has <b>NOT</b> expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <b>Items 11 To 20 below concern document(s) or information included:</b> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information. PTO Form 1449, 3 sheets of drawings, and 7 pages of Sequence Listing		

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.51) <b>Unknown 89563</b>	INTERNATIONAL APPLICATION NO. <b>PCT/JP00/05170</b>	ATTORNEYS DOCKET NUMBER <b>159-72</b>
21. <input checked="" type="checkbox"/> The following fees are submitted:		<b>CALCULATIONS</b> PTO USE ONLY
<b>BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5)):</b> -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....\$1040.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....\$890.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO .....\$740.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....\$710.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....\$100.00		
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		\$ 890.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).		\$ 0.00
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total Claims	14	-20 = 0
Independent Claims	2	-3 = 0
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)		\$280.00
<b>CLAIM FEES ARE NOT BEING PAID AT THIS TIME TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$ 890.00</b>
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		\$ 0.00
<b>SUBTOTAL =</b>		<b>\$ 890.00</b>
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).		\$ 0.00
<b>TOTAL NATIONAL FEE =</b>		<b>\$ 890.00</b>
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property		\$ 40.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1280.00 - Small Entity = \$640.00)		\$ 0.00
<b>TOTAL FEES ENCLOSED =</b>		<b>\$ 930.00</b>
		Amount to be:
		refunded \$
		Charged \$
a. <input checked="" type="checkbox"/> A check in the amount of \$930.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input checked="" type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.		
<b>NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>		
<b>SEND ALL CORRESPONDENCE TO:</b>  NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 <sup>th</sup> Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000		
 SIGNATURE		
<b>B. J. Sadoff</b> NAME		
<b>36,663</b> REGISTRATION NUMBER		<b>April 2, 2002</b> Date

RECEIVED PCT/PTO

13 AUG 2002

10089563.040202 #4

10/089563

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

YOSHIHARA, N. et al.

Atty. Ref.: 159-72

Serial No. 10/089,563

Group:

US National Phase of PCT/JP00/05170

Filed: April 2, 2002

Examiner:

For: KITS FOR EXTRACTING NUCLEIC ACID AND METHOD OF EXTRACTING  
NUCLEIC ACID BY USING THE KITS

\* \* \* \* \*

August 13, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**AMENDMENT**

Responsive to the Notification dated June 13, 2002 (copy attached), entry and  
consideration of the following amendments and remarks are requested.

**IN THE SPECIFICATION**

Amend the specification as follows:

Insert the attached Sequence Listing in place of the originally-filed copy of the  
same.

**REMARKS**

The specification has been amended to include the attached Sequence Listing.

YOSHIHARA, N. et al.  
Serial No. **10/089,563**  
US National Phase of PCT/JP00/05170


The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added. A separate Statement to this effect is attached.

An early and favorable Action on the merits is requested.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



B. J. Sadoff  
Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

YOSHIHARA, N. et al.

Atty. Ref.: 159-72

Serial No. unknown

Group:

US National Phase of PCT/JP00/05170

Filed: April 2, 2002

Examiner:

For: KITS FOR EXTRACTING NUCLEIC ACID AND METHOD OF EXTRACTING  
NUCLEIC ACID BY USING THE KITS

\* \* \* \* \*

April 2, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**PRELIMINARY AMENDMENT**

In order to place the above-identified application in better condition for examination, please amend the application as follows:

**IN THE SPECIFICATION**

Please substitute the following paragraphs in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Page 1, before the first line, please insert as a separate paragraph:

This application is the US national phase of international application PCT/JP00/05170 filed 02 August 2000, which designated the US.

### **IN THE CLAIMS**

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

3. (Amended) The nucleic acid isolation kit of Claim 1 wherein the nucleic acid is RNA.
4. (Amended) The nucleic acid isolation kit of Claim 1 wherein the reducing agent is 2-mercaptoethanol or dithiothreitol.
5. (Amended) The nucleic acid isolation kit of Claim 1 wherein the coprecipitant is glycogen or dextran.
6. (Amended) The nucleic acid isolation kit of Claim 1 wherein the protein denaturant is guanidine thiocyanate.
10. (Amended) The method of Claim 7 comprising adding a protein denaturant during alcohol precipitation.

YOSHIHARA, N. et al.

Serial No. **unknown**

US National Phase of PCT/JP00/05170

11. (Amended) The method of Claim 7 wherein the biological component is a body fluid or a blood product.

12. (Amended) The method of Claim 7 wherein the biological sample has a volume of 30  $\mu$ l to 100  $\mu$ l.

13. (Amended) The method of Claim 7 comprising no step of adding a salt.

14. (Amended) The method of Claim 7 wherein said steps are performed in a single 0.5 ml tube.

YOSHIHARA, N. et al.

10089563 .040202

Serial No. **unknown**

US National Phase of PCT/JP00/05170

**REMARKS**


Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is captioned "**Version With**

**Markings To Show Changes Made.**"

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



B. J. Sadoff  
Reg. No. 36,663

BJS:ecb  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100



YOSHIHARA, N. et al.

Serial No. **unknown**

US National Phase of PCT/JP00/05170

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

Page 1, before the first line, please insert as a separate paragraph:

This application is the US national phase of international application PCT/JP00/05170 filed 02 August 2000, which designated the US.

**IN THE CLAIMS**

3. (Amended) The nucleic acid isolation kit of Claim 1 ~~to 2~~ wherein the nucleic acid is RNA.
4. (Amended) The nucleic acid isolation kit of ~~any one of Claims 1 to 3~~ wherein the reducing agent is 2-mercaptoethanol or dithiothreitol.
5. (Amended) The nucleic acid isolation kit of ~~any one of Claims 1 to 4~~ wherein the coprecipitant is glycogen or dextran.
6. (Amended) The nucleic acid isolation kit of ~~any one of Claims 1 to 5~~ wherein the protein denaturant is guanidine thiocyanate.
10. (Amended) The method of ~~any one of Claims 7 to 9~~ comprising adding a protein denaturant during alcohol precipitation.

11. (Amended) The method of ~~any one of Claims 7 to 10~~ wherein the biological component is a body fluid or a blood product.

12. (Amended) The method of ~~any one of Claims 7 to 10~~ wherein the biological sample has a volume of 30  $\mu$ l to 100  $\mu$ l.

13. (Amended) The method of ~~any one of Claims 7 to 11~~ comprising no step of adding a salt.

14. (Amended) The method of ~~any one of Claims 7 to 12~~ wherein said steps are performed in a single 0.5 ml tube.

## SPECIFICATION

KITS FOR EXTRACTING NUCLEIC ACID AND METHOD OF  
EXTRACTING NUCLEIC ACID BY USING THE KITS5 TECHNICAL FIELD

The present invention relates to nucleic acid isolation kits and nucleic acid isolation methods using said kits.

BACKGROUND ART

- 10 Detection of target nucleic acids such as specific DNA or RNA in biological samples such as blood and saliva is very important not only in the field of research but also in the clinical field.
- For example, the rapid increase in the number of
- 15 patients with human immunodeficiency virus (HIV) infection or AIDS in recent years is a matter of concern not only in Japan but also worldwide. A recent epidemiological tendency of HIV infection is a marked increase in the proportions of vertical infection or infection at younger
- 20 ages. In the clinical field, there is an earnest demand for the development of an accurate and rapid genetic diagnosis. In Japan, the main infection route of HIV infection or AIDS especially in hemophiliacs is thought to be transfusion of blood including blood products. However,
- 25 little detail has been elucidated for the infection route from blood products (Lin Qi Zhang, Peter Simmonds, Christopher A. Ludlam and Andrew J. Leigh Brown (1991), AIDS, pp. 675-681). It is also important to follow up the

progress of HIV decrease in patients undergoing AIDS therapy.

Currently, an indirect detection method based on HIV antigen-antibody reaction has been established and become a major diagnostic means in laboratories. However, detection based on antigen-antibody reaction has been associated with the problem of a window period especially in screening. This is a time-lag between antigen infection and antigen or antibody production. For early clinical diagnosis of HIV infection, it is important to accurately, directly and rapidly detect the presence of HIV RNA in blood as an alternative to the indirect method based on antigen-antibody reaction. It is highly desirable to develop a new detection method that can be performed on smaller amounts of samples with higher sensitivity and at reduced cost and with a shortened window period. It is necessary to diagnose HIV infection from very small amounts of samples especially in infection in children or vertical infection.

Direct and rapid assay of HIV itself has become possible with the new introduction of molecular biological techniques such as polymerase chain reaction (PCR) or screening, for example, into clinical applications (Gerald Schochetman and John J. Sninsky (1991), "Direct Detection of Human Immunodeficiency Virus Infection Using the Polymerase Chain Reaction" Springer-Verlag pp. 90-110; Janet S. Bootman, Pete A. Kitchin (1994), J. Virological Methods, pp. 1-8; Anne-Mieke Vandamme, Sonia Van Dooren, Wessel Kok, Patrick Goubau, Katrien Fransen, Tim Kievits,

Jean-Claude Schmit, Erik De Clercq, Jan Desmyter (1995), J. Virological Methods pp. 121-132; E. Lyamuya, U. Bredberg-Raden, J. Albert, O. Grankvist, V. Msangi, C. Kagoma, F. Mhalu, and G. Biberfeld (1997), J. Clinical Microbiology, 5 pp. 278-280). Such nucleic acid detection systems combining nucleic acid isolation with nucleic acid amplification reactions such as PCR consist of three distinct processes: i.e., nucleic acid isolation, amplification and detection. Nucleic acid isolation is an 10 important process for subsequent amplification and detection, and if a nucleic acid isolation technique can be improved, the efficiency of amplification and detection will increase.

Currently, several types of total RNA isolation 15 methods are known and a plurality of kits are commercially available (John M. Chirgwin, Alan E. Przybyla, Raymond J. MacDonald and William J. Rutter (1979), Biochemistry pp. 5294-5299; Osamu Yamada, Toshiya Matsumoto, Masahiro Nakashima, Shinobu Hagari, Toshio Kamahora, Hiroshi Ueyama, 20 Yuichiro Kishi, Hidetoshi Uemura and Takashi Kurimura (1990), J. Virological Methods pp. 203-210).

However, these methods have disadvantages including the use of organic solvents such as phenol or chloroform to remove proteins and the necessity of changing tubes many 25 times during the isolation process. Further, they are not ideal for isolation from very small amounts of samples, especially blood products or blood samples from children. They also have the disadvantage that costs add up when a

number of samples are assayed in screening or the like.  
Thus, it has become increasingly important to develop a  
rapid and inexpensive HIV RNA detection system.

In recent years, several types of methods for  
5 isolating a nucleic acid, especially RNA have come to be  
known such as the guanidinium cyanate-phenol-chloroform  
(AGPC) method (Piotr Chomczynski, Nicolette Sacchi (1987),  
Analytical Biochemistry pp. 156-159) and methods using  
CsCl<sub>2</sub> or a resin (Maniatis T. et al.: Molecular Cloning: A  
10 laboratory manual, 2nd ed., Cold Spring Harbor 1989).  
Japanese Patent Public Disclosure No. 236499/1995  
incorporated herein as reference discloses an improved AGPC  
method for isolating a viral nucleic acid, in which the  
isolation process can be completed in a single tube without  
15 using an organic solvent.

#### SUMMARY OF THE INVENTION

An object of the present invention is to provide a  
nucleic acid isolation kit comprising a reducing agent, a  
coprecipitant and a protein denaturant characterized in  
20 that it contains no protease.

The nucleic acid isolation kit of the present  
invention is preferably an RNA isolation kit.

Another object of the present invention is to provide  
a method for isolating a nucleic acid from a biological  
25 sample, comprising:

i) incubating the biological sample with a reducing  
agent, a coprecipitant and a protein denaturant to degrade  
and denature proteins and other contaminants in the

biological sample without using a protease, and

ii) directly performing alcohol precipitation with a lower alcohol.

#### BRIEF DESCRIPTION OF DRAWINGS

5        FIG. 1 is a set of electrophoretic pattern of reaction products after nucleic acid isolation at varying glycogen concentrations and amplification.

FIG. 2 is a flowchart of a preferred embodiment of a nucleic acid isolation method of the present invention.

10       FIG. 3 shows the sequences of nucleic acids isolated by a method of the present invention.

#### DETAILED DESCRIPTION OF THE INVENTION

Methods for nucleic acid detection consist of three main processes, i.e., nucleic acid isolation, amplification  
15    and detection. Improvements in the nucleic acid isolation process are also important for the subsequent amplification and detection processes.

Before the present invention was made, the isolation technique used in many nucleic acid detection methods was  
20    the AGPC method described above. The present inventors found a novel method for isolating a nucleic acid from a sample by using an improved AGPC method in combination with a coprecipitant, to accomplish the present invention. The details are described below.

#### Nucleic acid isolation kits

Specifically, the present invention provides a nucleic isolation kit comprising a reducing agent, a coprecipitant and a protein denaturant characterized in

that it contains no protease.

A key feature of the present invention is that no protease is used. In conventional methods, non-specific proteases such as proteinase K, pronase and subtilisin are first used to remove proteins from biological samples. In the present invention, nucleic acids can be efficiently isolated only with a coprecipitant and a protein denaturant without using such a protease.

i) Reducing agents

10 In the present invention, reducing agents include, but are not limited to, 2-mercaptoethanol, dithiothreitol, etc. These reducing agents are used for protection of sulfhydryl groups in proteins or for reductive cleavage of disulfide bonds.

15 Reducing agents can be preferably used at a concentration of, but not specifically limited to, about 1%. Reducing agents may be added to nucleic acids as premixes in protein denaturants.

ii) Coprecipitants

20 In the present invention, coprecipitants are not specifically limited to, and any coprecipitants that can function as carriers for coprecipitating nucleic acids are suitable. Preferred examples of coprecipitants are macromolecular polysaccharides such as glycogen and  
25 dextran.

Glycogen is a polymer of D-glucose having a molecular weight of one million to several millions and is known as one of the most potent carriers for nucleic acid



precipitation (Steven Tracy (1981), Biochemistry pp. 251-268), and several types of commercially available glycogen can be used for in vitro applications. In the present invention, glycogen from slipper limpet is preferred from  
5 the viewpoints of cost and detection sensitivity.

The concentration of coprecipitants is not specifically limited, but as an example, glycogen from slipper limpet is used at 0.1 mg/ml to 2.0 mg/ml, preferably 0.2 mg/ml to 2.0 mg/ml, most preferably about  
10 0.2 mg/ml (Example 2).

iii) Protein denaturants

Suitable protein denaturants are those known to be able to solubilize proteins. They include, but not specifically limited to, guanidine thiocyanate and urea.  
15 Guanidine thiocyanate is especially preferred. A preferred embodiment of the present invention uses glycogen as a coprecipitant and guanidine thiocyanate as a protein denaturant, and is called the glycogen-guanidinium (GG) method.

20 Protein denaturants can be used at a final concentration of 3 M to 7 M, preferably 4 M to 6 M, most preferably approximately 4.5 M. Preferably, protein denaturants at the saturation concentration can solubilize proteins and efficiently reduce RNases that may be included  
25 in biological samples particularly in the case of isolation of RNA.

Preferably, protein denaturants are added to reactants after biological samples are mixed with

coprecipitants. As described above, they may be added as premixes with reducing agents to reaction solutions.

Further, without ant limitation, protein denaturants can be optionally added to an alcohol during alcohol precipitation at the final stage of the isolation process to more clearly remove contaminant proteins especially in the case of samples containing a lot of contaminants such as blood products. Protein denaturants are added to an alcohol during the alcohol precipitation step preferably at 0.5 M to 2.0 M, most preferably about 0.9 M (Example 3).

In the present invention, there is no special need to externally add a salt during the nucleic acid isolation process, and nucleic acid isolation kits specially require no salt. Moreover, the pH need not be specially externally adjusted.

#### Nucleic acid isolation methods

The present invention also provides methods for isolating a nucleic acid from a biological sample.

Methods of the present invention comprises:

- 1) incubating the biological sample with a reducing agent, a coprecipitant and a protein denaturant to degrade and denature proteins and other contaminants in the biological sample without using a protease, and
- 11) directly performing alcohol precipitation with a lower alcohol.

In the present invention, nucleic acid isolation can be normally made from biological samples in a volume of about 50  $\mu$ l, preferably 30  $\mu$ l to 100  $\mu$ l. This means that

significantly smaller amounts of biological samples are required than conventional methods.

According to a preferred but non-limitative embodiment, a biological sample is mixed with a coprecipitant and then a reducing agent and a protein denaturant are added in step i).

In step i), incubation takes place at 55°C - 65°C, preferably about 60°C for 5 minutes to 15 minutes, preferably about 10 minutes. Most preferably, incubation takes place at about 60°C for about 10 minutes. Incubation can be performed in an apparatus such as, but not limited to, an incubator, PCR apparatus (eg, Thermal Cycler® from Perkin-Elmer), etc.,

In step ii), the reaction mixture obtained in step i) is then combined with a lower alcohol to precipitate a nucleic acid. Alcohol precipitation can be performed by known techniques. Suitable alcohols include isopropanol and ethanol or the like. Preferably, isopropanol is added at a final concentration of 40% or more or ethanol is added at a final concentration of 70% or more. Then, the mixture may be cooled at -70°C to 4°C after addition of a lower alcohol to promote efficacy of salting out.

A protein denaturant may be added during alcohol precipitation as described above. This can remove contaminants precipitating with a target nucleic acid.

Alcohol precipitation is followed by centrifugation at 14,000 x g to 19,000 x g for 5 minutes to 15 minutes. Centrifugation may be performed at room temperature or

under cooling at about 4°C. After centrifugation, the supernatant is decanted or sucked to recover the precipitated nucleic acid.

Finally, the obtained nucleic acid can be washed with 70% ethanol, for example, and redissolved in a suitable solution into a ready-to-use state.

All the steps of the isolation process described above can be performed in a single tube. This can prevent contamination which may otherwise be caused by a change of tubes during the isolation process. This is especially important particularly when the nucleic acid is amplified by PCR or the like. Moreover, the isolation process of the present invention can be performed in a 0.5 ml tube in contrast to conventional methods that required a tube of at least 1.5 ml or more in size. Thus, the necessary amount of each reagent can be reduced and also the nucleic acid redissolved in a 0.5 ml tube can be directly used for amplification reaction.

A preferred but non-limitative embodiment of the present invention is shown in Example 1 and Fig. 2.

Nucleic acid isolation methods of the present invention described above can be applied to isolate both DNA and RNA. Preferably, they can be used for RNA isolation. In addition to RNA of the AIDS virus HIV described in the examples below, they can be clinically applied to type C hepatitis virus (HCV), influenza virus, type A hepatitis virus and the like. In addition to blood samples such as serum and plasma, they are also useful for

soluble liquid samples such as cerebrospinal fluid, saliva, semen and urine. They can also be used for powdered blood products derived from plasma or serum so that they have wide applications. Particularly, they are effective for small amounts of samples such as samples from children or powdered blood products.

Nucleic acids isolated by methods of the present invention can be subsequently amplified and detected, if necessary. That is, methods of the present invention can be combined with amplification techniques such as PCR to detect even very small amounts of nucleic acids at low concentrations that could not be detected by conventional methods.

#### Amplification

##### 15 (1) Reverse transcription reaction

When the target nucleic acid is an RNA such as viral RNA, the RNA can be reversely transcribed with a reverse transcriptase capable of converting the RNA into cDNA directly in the tube used for isolation. That is, the RNA isolated by methods of the present invention is highly pure and contains no substances inhibiting reverse transcription reaction. Suitable reverse transcriptases include, for example, a reverse transcriptase derived from avian myeloblastosis virus used in Example 1 described below.

##### 25 (2) Amplification of nucleic acids

Nucleic acids isolated by methods of the present invention can be amplified by known nucleic acid amplification reactions such as polymerase chain reaction

(PCR) using primers specific to the nucleic acids directly in the case of DNA or after reverse transcription into cDNA in the case of RNA. Nucleic acids isolated by methods of the present invention are highly pure and they contain no  
5 substances inhibiting amplification reaction even though ordinary PCR techniques require strict conditions.

Amplification reaction of nucleic acids may be nested PCR involving first PCR with an outer primer pair of the target nucleic acid followed by second PCR with an inner  
10 primer pair as described in Example 1 below, for example. The extent of amplification may vary with the affinity of the primer for the target nucleic acid. In HIV-1 described in the examples below, for example, gag primers and pol primers gave somewhat different extents of amplification  
15 and pol primers showed a higher detection sensitivity than gag primers.

#### Detection

Amplified nucleic acids can be detected and identified by standard techniques such as electrophoresis  
20 and sequencing. For example, they can be detected by ethidium bromide staining after electrophoresis on a polyacrylamide gel or an agarose gel. The sequence can also be identified by known methods using commercially available nucleic acid sequencers.

25 As described above, methods of the present invention achieve high cost efficiency, high sensitivity, safety and time reduction in nucleic acid isolation. They can be combined with amplification techniques such as PCR to

provide accurate, direct and rapid diagnosis for virus infection, for example. The GG method of the present invention can be applied not only to the field of research but also to the clinical field.

- 5       The following examples further illustrate the present invention but are not intended to limit the technical scope of the invention. Those skilled in the art can readily add modifications/changes to the present invention on the basis of the description of the specification, and those
- 10   modifications/changes are included in the technical scope of the present invention.

#### EXAMPLES

In the examples of the present invention, the following materials were used unless otherwise specified.

#### 15   Materials

##### (1) Samples

- In both AMPLICOR HIV-1 MONITOR® Test Kit (Roche) and NASBA Amplification System (Organon Teknika, Bostel, Netherlands), 26 samples containing high copy numbers of
- 20   HIV-1 RNA (30,000 copies or more / ml) and 47 samples containing low copy numbers below the detection limit (1,000 copies or less / ml) were used.

##### (2) Glycogen

- Oyster glycogen (Sigma), slipper limpet glycogen
- 25   (Sigma), rabbit glycogen (Sigma) or bovine glycogen (Sigma) was used.

##### (3) RNA isolation methods used as controls

The following commercially available 7 kits/methods

were used as controls of the present invention in the examples.

TRIZOL LS®

ISOGEN LS® (Nippon Gene)

5 RNA Isolation Technique (Stratagene)

SepaGene-RV® (Sanko Junyaku)

NASBA RNA Isolation Kit (Organon Teknika)

Smitest® (SUMITOMO METAL INDUSTRIES., LTD)

Cartrimox (Iowa Biotechnology).

10 Example 1: RNA isolation by the GG method and amplification and detection of the isolated RNA

HIV-1 RNA was isolated, amplified and detected from HIV-1-containing samples by the following procedures.

a. RNA isolation

15 RNA was isolated from samples following the scheme shown in Fig. 2 as an example of the GG method of the present invention.

In a 0.5 ml tube, 1 µl of glycogen (10 mg/ml) was added to 50 µl of each sample and the tube was agitated.

20 The tube was incubated at 60°C for 10 minutes with 150 µl of 6 M guanidine thiocyanate containing 1% 2-mercaptoethanol (2ME). Then, 200 µl of isopropanol was added. The tube was centrifuged at 15,000 g for 15 minutes at room temperature, and then the supernatant was removed.

25 400 µl of 70% ethanol containing 0.9 M guanidine thiocyanate was added. The tube was centrifuged at 15,000 g for 5 minutes at room temperature, and then the supernatant was removed. 400 µl of 70% ethanol was added.



The tube was centrifuged at 15,000 g for 5 minutes at room temperature, and then the supernatant was removed. The residue was dissolved in 10 µl of RNase-free sterile water.

b. Amplification

5 1) Primers

For amplification of HIV-1 RNA, gag and/or pol primers (SEQ ID NOS: 1-8) shown in Table 1 below were used (derived from a human retrovirus of AIDS obtained from Los Alamos National Laboratory).

10

Table 1

Primer	Sequence	Location	SEQ ID NO:
GF62	AAGGATAGAGGTAAGACACCA	gag 270-292	1
GF63	TAGCTGCTGGTCCAATGCTTTTA	gag 1022-999	2
15 SK100	ATCAAGCAGCCATGCAAAT	gag 581-599	3
SK104	CTTTTGGTCCTTGCTTATGTC	gag 871-859	4
UNIPOL 1B	AGTGGATATATAGAAGCAGAAGT	pol 2385-2407	5
UNIPOL 1A	CCCCCAATCCCCCTTTTCTTTTAAAA	pol 2722-2696	6
P5	ATTAGCAGGAAGATGGCC	pol 2453-2470	7
20 P6	TACTCCTTGACTTTGGGG	pol 2594-2577	8

The primer pair GF62 and GF63 and the primer pair UNIPOL 1B and UNIPOL 1A are outer primer pairs of gag and pol, respectively. On the other hand, the primer pair SK100 and SK104 and the primer pair P5 and P6 are inner primer pairs of gag and pol, respectively.

2) PCR

The RNA isolated as above was used for nucleic acid

amplification by a conventional PCR method.

- i) Initially, 2 drops of mineral oil was added to a 0.5 ml tube containing the above isolated RNA dissolved in 10  $\mu$ l of sterile water and the tube was momentary spun.
- 5 Then, the tube was incubated at 80°C for 10 minutes in a Thermal Cycler® (Perkin-Elmer) to destroy any RNA complexes or secondary structures that may disturb priming in PCR. After 10 minutes, the tube was immediately transferred into ice to stop the reaction and momentary spun.
- 10 ii) Then, 15  $\mu$ l of a mixture for RT having the composition shown in Table 2 below was added and the tube was vortexed and momentary spun.

Table 2. Composition of mixture for RT

15	H <sub>2</sub> O	7.13
	x 10 PCR buffer	2.5
	10 mM MgCl <sub>2</sub>	2.0
	10 mM DTT	0.5
	2.5 mM dNTP	1.5
20	1 $\mu$ l/ml Primer 1 (outer)	0.25
	1 $\mu$ l/ml Primer 2 (outer)	0.25
	10 U/ $\mu$ l RNase inhibitor	0.77
	2.5 U/ $\mu$ l Reverse transferase (AMVRT)	0.1
	Total	15.00 $\mu$ l

25

The tube was incubated in a warm bath (42°C) for 60 minutes to synthesise cDNA from mRNA. Then, the tube was momentary spun.

iii) Then, the tube was incubated at 99°C for 6 minutes in a Thermal Cycler to denature double stranded mRNA-cDNA into single strands. After 6 minutes, the tube was immediately transferred into ice to stop the reaction and momentary spun.

iv) Then, 75 µl of a mixture for first PCR having the composition shown in Table 3 below was added and the tube was vortexed and momentary spun.

Table 3. Composition of mixture for first PCR

H <sub>2</sub> O	58
x 10 PCR buffer	7.5
10 mM MgCl <sub>2</sub>	3.0
2.5 mM dNTP	4.5
1 µl/ml Primer 1 (outer)	0.75
1 µl/ml Primer 2 (outer)	0.75
Taq polymerase	0.5
Total	75.00 µl

First PCR was performed in a Thermal Cycler. Specifically, 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute were performed. Then, the tube was incubated at 72°C for 10 minutes and then, the reaction was stopped at 4°C.

v) Then, 10 µl of the first PCR product obtained in iv) and mineral oil were added to a fresh 0.5 ml tube, and the tube was momentary spun. Then, the tube was incubated at 99°C for 6 minutes in a Thermal Cycler to denature

double-stranded DNA into single strands. After 6 minutes, the tube was immediately transferred into ice to stop the reaction and momentary spun.

- vi) Then, 90  $\mu$ l of a mixture for second PCR having the composition shown in Table 4 below was added and the tube was vortexed and momentary spun.

Table 4. Composition of mixture for second PCR

	H <sub>2</sub> O	66.5
10	x 10 PCR buffer	10
	10 mM MgCl <sub>2</sub>	5
	2.5 mM dNTP	6
	1 $\mu$ l/ml Primer 3 (inner)	1
	1 $\mu$ l/ml Primer 4 (inner)	1
15	Taq polymerase	0.5
	Total	90.0 $\mu$ l

- Second PCR was performed in a Thermal Cycler. Specifically, 30 or 40 cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute were performed. Then, the tube was incubated at 72°C for 10 minutes and then, the reaction was stopped at 4°C.

#### c. Detection

##### Electrophoresis and staining

- Following amplification, PCR products were electrophoresed. Specifically, a dye was added to the second PCR product and an aliquot of 10  $\mu$ l was loaded on a 5% acrylamide gel or a 2% agarose gel and electrophoresed.

HaeIII digest of  $\Phi$ X174 (Roche) was used as a molecular weight marker. Culture supernatant of an HIV-1 infected cell line MOLT-4/HTLV III was used as a positive control. After completion of migration, bands were visualized by ethidium bromide staining.

Example 2: Optimal concentration of glycogen used for RNA isolation

The concentration of glycogen used as a carrier was diversified to determine the optimal concentration from the viewpoints of isolation efficiency, time reduction and cost efficiency.

Specifically, samples containing low copy numbers of HIV-1 defined above were used to isolate RNA by the GG method of the present invention described above except that 1  $\mu$ l each of glycogen at a concentration of 0, 5, 10, 50 or 100 mg/ml was used and the concentration was changed to a final value of 0, 0.1, 0.2, 1 or 2 mg/ml. Isolated RNA was amplified over 30 or 40 cycles of PCR. The primers used for amplification were a gag primer pair of SK 100 and SK 104 and a pol primer pair of P5 and P6. Theoretically, it is expected that 291 bp and 142 bp of PCR products are obtained with the gag and pol primer pairs, respectively.

One  $\mu$ l of a dye was added to 9  $\mu$ l of the second PCR product and the mixed product was loaded on a 5% polyacrylamide or 2.0% agarose gel and electrophoresed. Bands were detected by ethidium bromide staining.

The results are shown in Fig. 1. In Fig. 1, panels A, B and C show the results after 30 cycles with the gag

primer pair, 40 cycles with the gag primer pair and 30 cycles with the pol primer pair, respectively. Lanes 1-5 in each panel represent bands at glycogen concentrations of 0 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 1 mg/ml and 2 mg/ml,

5 respectively. Lane 6: positive control (P); lane 7: negative control (N); M: molecular weight marker (Roche).

As shown in Fig. 1, bands were detected at glycogen concentrations of 0.2 mg/ml to 2 mg/ml (lanes 3-5) in each case. Therefore, glycogen can function as a carrier at a  
10 concentration of about 0.2 mg/ml or more.

Example 3: Optimal concentration of guanidine thiocyanate used for RNA isolation

The concentration of guanidine thiocyanate added to 70% ethanol during the final ethanol washing step was  
15 changed to determine the optimal concentration from the viewpoint of isolation efficiency.

Specifically, samples containing low copy numbers of HIV-1 defined above were used to isolate RNA by the GG method of the present invention described above except that  
20 the concentration of guanidine thiocyanate added to 70% ethanol during the final ethanol washing step was changed to 0.0 M, 0.6 M, 0.7 M, 0.8 M, 0.9 M and 1.0 M.

As a result, small amounts of contaminants remained as masses in the final RNA at a guanidine thiocyanate  
25 concentration of 0.8 M or less but disappeared at 0.9 M or more.

Example 4: Comparison of RNA isolation efficiency

The efficiency of the GG method of the present

invention was compared with those of commercially available known RNA or DNA isolation kits on HIV samples.

Specifically, seven widely used commercial RNA or DNA isolation kits were adopted as controls to perform nucleic acid isolation according to the ordinary protocol of each kit. For each kit, 26 high copy-number samples and 47 low copy-number samples described above were used. Nucleic acids were amplified by PCR with the gag primer pair and/or pol primer pair described above and detected as described above.

The results are shown in Table 5 below.

Table 5

	Isolation	GG method	A	B	C	D
	method					
15	High copy	26/26	10/26	12/26	12/26	10/26
		26/26	10/26	12/26	12/26	10/26
		26/26	11/26	11/26	12/26	9/26
		(100)	(39.7)	(44.9)	(46.2)	(37.2)
20	Low copy	38/47	0/47	0/47	0/47	0/47
		38/47	0/47	0/47	0/47	0/47
		37/47	0/47	0/47	0/47	0/47
		(80.2)	(0)	(0)	(0)	(0)

25

	Isolation method	E	F	G
	High copy	10/26	26/26	26/26
		10/26	26/26	26/26
5		10/26	26/26	26/26
		(38.5)	(100)	(100)
	Low copy	0/47	33/47	36/47
		0/47	33/47	36/47
10		0/47	32/47	35/47
		(0)	(69.5)	(75.9)

In high copy-number samples, detection was about 35% to about 50% with control kits A to E and 100% with F or G kit. In contrast, the method of the present invention achieved detection of 100%. In low copy-number samples, detection was 0% with control kits A to E and about 70% with F or G kit in contrast to the method of the present invention that achieved detection of 80.2% even in low copy-number samples.

This demonstrates that the present invention shows significantly excellent isolation efficiency as compared with many existing RNA isolation methods.

Example 5: Identification of the sequences of amplified nucleic acids

Amplified samples were sequenced.

Specifically, an automated sequencer ABI-PRISM® 310 (Perkin-Elmer) was used for direct sequencing as



recommended by the manufacturer. The target region in this Example is the gag or pol region of HIV-1. The reference sequence was retrieved from the annual report of the Los Alamos National Laboratory. Phylogenetic trees were used  
5 for data analysis.

The results on PCR products using the gag primer pair are shown in Fig. 3 and SEQ ID NOS: 10-19. The nucleotide sequences of nucleic acids can be determined in all the samples subjected to RNA isolation by the GG method of the  
10 present invention. Sequencing of 10 samples revealed a common sequence of subtype E (Fig. 3). Sequence data show that all the 10 samples tested have a 90% or more homology with the common sequence (SEQ ID NO: 9) in the gag region of HIV-1 (291 bp). In Fig. 3, bases identical to those of  
15 the common sequence are shown by "-".

This verifies that each sample subjected to nucleic acid isolation contains HIV-1 RNA and that the presence of HIV-1 was detected by isolation and amplification of the RNA.

#### 20 EFFECT OF THE INVENTION

We compared known isolation methods using commercial kits with a method of the present invention. The results showed that the method of the present invention was the most excellent isolation method from the viewpoints of  
25 detection sensitivity, economy and time reduction.

Conventional methods using  $\text{CsCl}_2$  or a resin were suitable in terms of time reduction, but inferior to the method of the present invention in detection sensitivity.

The method of the present invention is safer than the AGPC method because it uses neither phenol nor chloroform. Moreover, the necessary period is within 60 minutes, which is shorter than required by conventional methods because  
5 any organic solvents such as phenol and chloroform are not used. The method of the present invention can be performed more inexpensively on small amounts (about 50  $\mu$ l) of samples. All the steps of the method of the present invention can be performed in a 0.5 ml tube with no need to  
10 change the tube. Thus, processes from nucleic acid isolation to amplification can be completed in a single step, whereby the risk of contamination of reaction products is decreased.

Without being bound to any theory, the excellent  
15 isolation efficiency of the method of the present invention is partially attributed to the use of glycogen as a carrier of nucleic acids. The present invention is particularly useful for screening small amounts of samples such as blood products or blood samples from children, for example, and  
20 for following up patients under AIDS therapy, and it is useful for not only the field of research but also clinical applications.

## CLAIMS

1. A nucleic acid isolation kit comprising a reducing agent, a coprecipitant and a protein denaturant characterized in that it contains no protease.
2. The nucleic acid isolation kit of Claim 1, which is salt-free.
3. The nucleic acid isolation kit of Claim 1 or 2 wherein the nucleic acid is RNA.
4. The nucleic acid isolation kit of any one of Claims 1 to 3 wherein the reducing agent is 2-mercaptoethanol or dithiothreitol.
5. The nucleic acid isolation kit of any one of Claims 1 to 4 wherein the coprecipitant is glycogen or dextran.
6. The nucleic acid isolation kit of any one of Claims 1 to 5 wherein the protein denaturant is guanidine thiocyanate.
7. A method for isolating a nucleic acid from a biological sample, comprising:
  - i) incubating the biological sample with a reducing agent, a coprecipitant and a protein denaturant to degrade and denature proteins and other contaminants in the biological sample without using a protease, and
  - ii) directly performing alcohol precipitation with a lower alcohol.
8. The method of Claim 7 wherein incubation takes place at 55°C to 65°C for 5 minutes to 15 minutes in step i).
9. The method of Claim 8 wherein incubation takes place at about 60°C for about 10 minutes in step i).

10. The method of any one of Claims 7 to 9 comprising adding a protein denaturant during alcohol precipitation.
11. The method of any one of Claims 7 to 10 wherein the biological component is a body fluid or a blood product.
12. The method of any one of Claims 7 to 10 wherein the biological sample has a volume of 30  $\mu$ l to 100  $\mu$ l.
13. The method of any one of Claims 7 to 11 comprising no step of adding a salt.
14. The method of any one of Claims 7 to 12 wherein said steps are performed in a single 0.5 ml tube.

## ABSTRACT


The present invention provides a nucleic acid  
isolation kit comprising a reducing agent, a coprecipitant  
and a protein denaturant characterized in that it contains  
5 no protease, and a method for isolating a nucleic acid  
using said kit.

*Fig.1*

A



B



C




Fig.2

## FLOWCHART OF THE GG METHOD




Fig.3

COMMON SEQUENCE E	80	90	100	110	120	130	140
SAMPLE 1	CTATGCAAT	gTAAAGAT	aCCATGATG	agGAGTCC	AGaTgGGAC	aGgtACAC	CAGTACATGC
SAMPLE 2	-----A	-----A	-----A	-----T	-----T	-----C	-----C
SAMPLE 3	-----A	-----A	-----A	-----C	-----T	-----C	-----C
SAMPLE 4	-----A	-----A	-----A	-----C	-----T	-----C	-----C
SAMPLE 5	-----A	-----A	-----A	-----C	-----T	-----C	-----C
SAMPLE 6	-----A	-----A	-----A	-----C	-----T	-----C	-----A
SAMPLE 7	-----G	-----G	-----C	-----C	-----T	-----C	-----C
SAMPLE 8	-----A	-----A	-----C	-----C	-----T	-----C	-----C
SAMPLE 9	-----A	-----A	-----C	-----C	-----T	-----C	-----C
SAMPLE 10	-----C	-----C	-----C	-----C	-----T	-----C	-----C
COMMON SEQUENCE E	80	90	100	110	120	130	140
SAMPLE 1	AGGCGCTATT	CCACGAGGC	AGATGAGAG	ACCAAGGGGA	agTGAATGAG	CAGGaaCTAC	TAGTACCTT
SAMPLE 2	-----A	-----A	-----G	-----G	-----G	-----A	-----A
SAMPLE 3	-----G	-----G	-----G	-----G	-----G	-----G	-----A
SAMPLE 4	-----G	-----G	-----G	-----G	-----G	-----G	-----A
SAMPLE 5	-----G	-----G	-----G	-----G	-----G	-----G	-----C
SAMPLE 6	-----G	-----G	-----G	-----G	-----G	-----G	-----C
SAMPLE 7	-----A	-----A	-----G	-----G	-----T	-----G	-----G
SAMPLE 8	-----G	-----G	-----G	-----G	-----G	-----G	-----G
SAMPLE 9	-----G	-----G	-----G	-----G	-----G	-----G	-----G
SAMPLE 10	-----G	-----G	-----G	-----G	-----G	-----G	-----G
COMMON SEQUENCE E	150	160	170	180	190	200	210
SAMPLE 1	CAAGRACAA	TAGaTGGAT	GRCaagCAAT	CCaCTaTCC	CaTgGGaGA	CaTCTATAA	
SAMPLE 2	-----G	-----A	-----A	-----A	-----A	-----A	
SAMPLE 3	-----G	-----A	-----A	-----A	-----A	-----A	
SAMPLE 4	-----G	-----A	-----A	-----A	-----A	-----A	
SAMPLE 5	-----G	-----A	-----A	-----A	-----A	-----A	
SAMPLE 6	-----G	-----A	-----A	-----A	-----A	-----A	
SAMPLE 7	-----G	-----A	-----A	-----A	-----A	-----A	
SAMPLE 8	-----G	-----A	-----A	-----A	-----A	-----A	
SAMPLE 9	-----G	-----A	-----A	-----A	-----A	-----A	
SAMPLE 10	-----G	-----A	-----A	-----A	-----A	-----A	



Case No. \_\_\_\_\_

Nixon &amp; Vanderhye P.C. (12/87)

**RULE 63 (37 C.F.R. 1.63)  
DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**KITS FOR EXTRACTING NUCLEIC ACID AND METHOD OF EXTRACTING NUCLEIC ACID BY USING THE KITS**

the specification of which (check applicable box(es)):

- ☐ is attached hereto  
☐ was filed on \_\_\_\_\_ as U.S. Application Serial No. \_\_\_\_\_  
☒ was filed as PCT international application No. PCT/JP00/05170 on August 2, 2000  
☐ and (if applicable to U.S. or PCT application) was amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number  
190633/1999

Country  
Japan

Day/Month/Year Filed  
5/7/1999

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.  
 Application Number \_\_\_\_\_ Date/Month/Year Filed \_\_\_\_\_

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT International applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application.

Prior U.S./PCT Application(s):  
 Application Serial No. \_\_\_\_\_

Day/Month/Year Filed \_\_\_\_\_

Status: patented  
 pending, abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8<sup>th</sup> Floor, Arlington, VA 22201-4714, telephone number (703) 816-0000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 26327; Larry S. Nixon, 25840; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nustbaum, 33349; Michael J. Keenan, 32105; Bryan H. Davidson, 32251; Stanley C. Spooner, 27393; Leonard C. Michael, 29006; Duane M. Dyers, 33363; Jeffrey H. Nelson, 30681; John R. Lissova, 33149; H. Warren Burnham, Jr. 29386; Thomas E. Byrne, 32206; Mary J. Wilson, 32955; J. Scott Davidson, 33483; Alan M. Kagen, 36178; William J. Griffin, 31260; Robert A. Molan, 29834; B. J. Sedorf, 36663; James D. Bergquist, 34776; Umdeep S. Gill, 37334.

1. Inventor's Signature: Namiko Date: April 1, 2002  
 Inventor: Namiko (first) Yoshihara (last) Japanese (citizenship)  
 Residence (city): Tokyo (state/country) Japan  
 Post Office Address: 2-14-25, Nukui, Nerima-ku, Tokyo 176-0021 Japan  
 (Zip Code) \_\_\_\_\_
2. Inventor's Signature: Hisako Suzuki Date: April 1, 2002  
 Inventor: Hisako (first) SUZUKI (last) Japanese (citizenship)  
 Residence (city): Saitama (state/country) Japan  
 Post Office Address: 2-9-6, Miyahara-cho, Saitama-shi, Saitama 330-0038 Japan  
 (Zip Code) \_\_\_\_\_
3. Inventor's Signature: Taichi Naka Date: April 1, 2002  
 Inventor: Taichi (first) NAKAMURA (last) Japanese (citizenship)  
 Residence (city): Saitama (state/country) Japan  
 Post Office Address: 2-10-3, Komuro, Ina-machi, Kikadachi-gun, Saitama 362-0806 Japan  
 (Zip Code) \_\_\_\_\_

FOR ADDITIONAL INVENTORS, check box ☒ and attach sheet with same information and signature and date for each.

**RULE 63 (37 C.F.R. 1.63)**  
**DECLARATION AND POWER OF ATTORNEY**  
**FOR PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

. Nixon & Vanderhye P.C. (12/97)

4. Inventor's Signature: Sachiko Manabe Date: April 1, 2002  
 Inventor: (first) MI (last) (citizenship)  
Tokyo (state/country) Japan  
 Residence: (city) 2-1-12-803, Kitaueno, Taifu-ku, Tokyo 110-0014 Japan  
 Post Office Address: (Zip Code)
5. Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Inventor: \_\_\_\_\_ (first) \_\_\_\_\_ MI \_\_\_\_\_ (last) \_\_\_\_\_ (citizenship)  
 Residence: (city) \_\_\_\_\_ (state/country) \_\_\_\_\_  
 Post Office Address: \_\_\_\_\_  
 (Zip Code) \_\_\_\_\_
6. Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Inventor: \_\_\_\_\_ (first) \_\_\_\_\_ MI \_\_\_\_\_ (last) \_\_\_\_\_ (citizenship)  
 Residence: (city) \_\_\_\_\_ (state/country) \_\_\_\_\_  
 Post Office Address: \_\_\_\_\_  
 (Zip Code) \_\_\_\_\_
7. Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Inventor: \_\_\_\_\_ (first) \_\_\_\_\_ MI \_\_\_\_\_ (last) \_\_\_\_\_ (citizenship)  
 Residence: (city) \_\_\_\_\_ (state/country) \_\_\_\_\_  
 Post Office Address: \_\_\_\_\_  
 (Zip Code) \_\_\_\_\_
8. Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Inventor: \_\_\_\_\_ (first) \_\_\_\_\_ MI \_\_\_\_\_ (last) \_\_\_\_\_ (citizenship)  
 Residence: (city) \_\_\_\_\_ (state/country) \_\_\_\_\_  
 Post Office Address: \_\_\_\_\_  
 (Zip Code) \_\_\_\_\_
9. Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Inventor: \_\_\_\_\_ (first) \_\_\_\_\_ MI \_\_\_\_\_ (last) \_\_\_\_\_ (citizenship)  
 Residence: (city) \_\_\_\_\_ (state/country) \_\_\_\_\_  
 Post Office Address: \_\_\_\_\_  
 (Zip Code) \_\_\_\_\_
10. Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Inventor: \_\_\_\_\_ (first) \_\_\_\_\_ MI \_\_\_\_\_ (last) \_\_\_\_\_ (citizenship)  
 Residence: (city) \_\_\_\_\_ (state/country) \_\_\_\_\_  
 Post Office Address: \_\_\_\_\_  
 (Zip Code) \_\_\_\_\_
11. Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Inventor: \_\_\_\_\_ (first) \_\_\_\_\_ MI \_\_\_\_\_ (last) \_\_\_\_\_ (citizenship)  
 Residence: (city) \_\_\_\_\_ (state/country) \_\_\_\_\_  
 Post Office Address: \_\_\_\_\_  
 (Zip Code) \_\_\_\_\_
12. Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Inventor: \_\_\_\_\_ (first) \_\_\_\_\_ MI \_\_\_\_\_ (last) \_\_\_\_\_ (citizenship)  
 Residence: (city) \_\_\_\_\_ (state/country) \_\_\_\_\_  
 Post Office Address: \_\_\_\_\_  
 (Zip Code) \_\_\_\_\_

## SEQUENCE LISTING

<110> Oriental Yeast Co., Ltd.

NAITOU Toshikuni

National Institute of Infectious Diseases

TAKEDA Yoshifumi

<120> Kits for extracting nucleic acid and method of extracting  
nucleic acid by using the kits

<130> YCT513

<160> 19

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<400> 1

aaggatagag gtaaaagaca cca 23

<210> 2

<211> 23

<212> DNA

<213> Artificial Sequence

<400> 2

tagctgcigg tccaaigcctt tta 23

<210> 3

<211> 19

<212> DNA

<213> Artificial Sequence

<400> 3

atcaagcagc catgcaaa1 19

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<400> 4

cttttgggtcc ttgtcttatg tc 22

<210> 5

<211> 23

<212> DNA

<213> Artificial Sequence

<400> 5

agttggatata tagaagcaga agt 23

<210> 6

<211> 27

<212> DNA

<213> Artificial Sequence

<400> 6

cccccaatcc ccccttttct ttlaaaa 27

<210> 7

<211> 18

<212> DNA

<213> Artificial Sequence

<400> 7

attagcagga agatggcc 18

<210> 8

<211> 18

<212> DNA

<213> Artificial Sequence

<400> 8

tactccttga ctttgggg 18

<210> 9

<211> 220

<212> DNA

<213> HIV-1

<400> 9

ctatgcaaat gttaaaagal accatcaalg aggaagctgc agaatgggac 50  
 agggctacac cagtaacalc agggccctatt ccaccaggcc agatgagaga 100  
 accaagggga agtgacatag caggaaactac tagtaccctt caagaacaaa 150  
 taggatggat gacaagcaat ccacctatcc cagtgggaga catctataaa 200  
 agatgggataa tcttgggatt 220

<210> 10

<211> 220

<212> DNA

<213> HIV-1

<400> 10

ccatgcaaat gttaaaagaa accatcaatg aggaagctgc agaatgggat 50  
 agggctacacc cagtacalc agggccctatt ccaccaggcc aaalgagggga 100  
 accaagggga agtgacatag caggaaactac tagtaacctt caagaacaaa 150  
 taggatggat gacaagcaat ccacctatcc cagtgggaga catctataaa 200

aggtggataa tctgggatt

220

&lt;210&gt; 11

&lt;211&gt; 220

&lt;212&gt; DNA

&lt;213&gt; HIV-1

&lt;400&gt; 11

ccatgcacaat gtlaaaagaa accalcaatg aggaagctgc agaatggat 50

agggtacacc cagtlacatgc agggccctatt ccaccaggcc agatgagga 100

accaaggsga agtgacatag cagggaactac tagtaacctt caagaacaga 150

taggatggat gacaaacaat ccacctatcc cagtgggaga catctalaaa 200

aggtggataa tctgggatt 220

&lt;210&gt; 12

&lt;211&gt; 220

&lt;212&gt; DNA

&lt;213&gt; HIV-1

&lt;400&gt; 12

ccatgcacaat gtlaaaagaa accatcaatg aggaagctgc agaatggat 50

agggtacacc cagtlacatgc agggccctatt ccaccaggcc agatgagga 100

accaaggsga agtgacatag cagggaactac tagtacctt caagaacaaa 150

taggatggat gacaaacaat ccacctatcc cagtgggaga catctalaaa 200

agatggataa tctgggatt 220

&lt;210&gt; 13

&lt;211&gt; 220

&lt;212&gt; DNA

&lt;213&gt; HIV-1

&lt;400&gt; 13

ccaigcaaat gtaaaaagaa accatcaatg aggaagctgc agaatgggat 50  
 aggttacacc caglacatgc agggcctatt ccaccaggcc agatgagggg 100  
 accaagggga agtgacatag caggaactac tagtaccctt caagagcaaa 150  
 taggatggat gacaaacaat ccacctatcc cagtgggaga catctataaa 200  
 aggtggataa tctgggatt 220

<210> 14

<211> 220

<212> DNA

<213> HIV-1

<400> 14

ccaigcaaat gtaaaaagaa accatcaatg aggaagctgc agaatgggat 50  
 aggttacacc caatacatgc agggcctatt ccaccaggcc agatgagggg 100  
 accaagggga agtgacatag caggaaccac tagtaccctt caagaacaaa 150  
 taggatggat gacaaacaat ccacctatcc cagtgggaga catctataaa 200  
 aggtggataa tctgggatt 220

<210> 15

<211> 220

<212> DNA

<213> HIV-1

<400> 15

ccaigcaaat gtaaaaagaa accatcaatg aggaagctgc agaatgggat 50  
 aggttacacc caglacatgc agggcctatt ccaccaggcc agatgagggg 100  
 accaagggga agtgacatag caggaactac tagtaccctt caagaacaaa 150  
 taggatggat gacaaacaat ccacctatcc cagtgggaga catctataaa 200  
 aggtggataa tctgggatt 220

<210> 16

&lt;211&gt; 220

&lt;212&gt; DNA

&lt;213&gt; HIV-1

&lt;400&gt; 16

ccatgcaaat gttaaaagag accatcaatg aggaagctgc agaatgggat	50
agggtacacc cagtacatgc agggcctatt ccaccaggcc agatgagggg	100
accaagggga agtgatatag caggaactac tagtaccctt caagaacaaa	150
taggatggat gacaagcaat ccacciatcc cagtgggaga catctataaa	200
aggtaggataa tcttgggatt	220

&lt;210&gt; 17

&lt;211&gt; 220

&lt;212&gt; DNA

&lt;213&gt; HIV-1

&lt;400&gt; 17

ccatgcaaat gttaaaagaa accatcaatg aggaagctgc agaatgggat	50
agggtacacc caglacatgc agggcctatt ccaccaggac agatgagggg	100
accaagggga agtgacatag caggaactac tagtaccctt caagaacaaa	150
taggatggat gacaagcaat ccactatcc cagtgggaga aatctataaa	200
aggtaggataa tcttgggatt	220

&lt;210&gt; 18

&lt;211&gt; 220

&lt;212&gt; DNA

&lt;213&gt; HIV-1

&lt;400&gt; 18

ccatgcaaat gttaaaagaa accatcaatg aggaagctgc agaatgggat	50
agggtacacc cagtacatgc agggcctatt ccaccaggcc agatgagggg	100
accaagggga agtgacatag caggaactac tagtaccctt caagaacaga	150



taggatggat gacaaacaal ccacctaacc cagigggaga catctataaa 200  
 aggtggataa tcttgggatl 220

<210> 19

<211> 220


<212> DNA

<213> HIV-1

<400> 19

ccatgcaaat gttaaaagac accatcaatg aggaagctgc agaatgggat 50  
 aggttacacc cagtacatgc agggcctatt ccaccaggcc agatgagggga 100  
 accaagggga aglgacalag caggaactac tagtaccctt caggaacaaa 150  
 taggatggat gacaaacaal ccacctaacc cagigggaga catctataaa 200  
 aggtggataa tcttgggatl 220

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not  
present  
for scanning. (Document title)

\* Scanned copy is best available. Drawing fig 1 is dark